PlainRecalls
FDA Drug Moderate Class II Ongoing

Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited. Colvale-Bardez, Goa - 403513, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-356-01

Reported: June 4, 2025 Initiated: May 15, 2025 #D-0452-2025

Product Description

Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited. Colvale-Bardez, Goa - 403513, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-356-01

Reason for Recall

OOS results reported for the Dissolution (by UV) test.

Details

Units Affected
8,520 100-count bottles
Distribution
Nationwide in the USA
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Theophylline (Anhydrous) Extended-Release Tablets, 600 mg, 100 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited. Colvale-Bardez, Goa - 403513, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. NDC: 68462-356-01. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 8,520 100-count bottles.
Why was this product recalled?
OOS results reported for the Dissolution (by UV) test.
Which agency issued this recall?
This recall was issued by the FDA Drug on June 4, 2025. Severity: Moderate. Recall number: D-0452-2025.